Calreticulin accelerates corneal wound closure and mitigates fibrosis: Potential therapeutic applications
Journal of Cellular and Molecular Medicine · 2024
DOI: 10.1111/jcmm.18027 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Cellular and Molecular Medicine, 2024. Verfasst von Sarita Mishra und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, Division of Precision Medicine, New York University School of Medicine Langone Health, New York, New York, USA. Hauptthemen laut MEDLINE: Calreticulin, Wound Healing, Fibrosis, Corneal Injuries. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 56 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Tissue Regeneration Sciences, Inc..
Abstract (Originalsprache)
The processes involved in regeneration of cutaneous compared to corneal tissues involve different intrinsic mechanisms. Importantly, cutaneous wounds involve healing by angiogenesis but vascularization of the cornea obscures vision. Previous studies showed that topically applied calreticulin (CALR) healed full‐thickness excisional animal wounds by a tissue regenerative process markedly enhancing repair without evoking angiogenesis. In the current study, the application of CALR in a rabbit corneal injury model: (1) accelerated full wound closure by 3 days (2) accelerated delayed healing caused by corticosteroids, routinely used to prevent post‐injury inflammation, by 6 days and (3) healed wounds without vascularization or fibrosis/hazing. In vitro, CALR stimulated proliferation of human corneal epithelial cells (CE) and corneal stromal cells (keratocytes) by 1.5‐fold and 1.4‐fold, respectively and induced migration of CE cells and keratocytes, by 72% and 85% compared to controls of 44% and 59%, respectively. As a marker of decreased fibrosis, CALR treated corneal wounds showed decreased immunostaining for α‐smooth muscle actin (α‐SMA) by keratocytes and following CALR treatment in vitro, decreased the levels of TGF‐β2 in human CE cells and α‐SMA in keratocytes. CALR has the potential to be a novel therapeutic both, to accelerate corneal healing from various injuries and in conjunction with corticosteroids.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Medicine, Division of Precision Medicine, New York University School of Medicine Langone Health, New York, New York, USA.
- Powered Research, Research Triangle Park, North Carolina, New York, USA.
- Department of Pathology, New York University School of Medicine Langone Health, New York, New York, USA.
ORCID-Profile: Leslie I Gold
Förderung
- Tissue Regeneration Sciences, Inc.
Zitieren
APA
Mishra, S., Manzanares, M. A., Prater, J., Culp, D., & Gold, L. I. (2024). Calreticulin accelerates corneal wound closure and mitigates fibrosis: Potential therapeutic applications. Journal of Cellular and Molecular Medicine. https://doi.org/10.1111/jcmm.18027
Vancouver
Mishra S, Manzanares MA, Prater J, Culp D, Gold LI. Calreticulin accelerates corneal wound closure and mitigates fibrosis: Potential therapeutic applications. Journal of Cellular and Molecular Medicine. 2024. doi:10.1111/jcmm.18027
BibTeX
@article{Mishra2024,
author = {Mishra, Sarita and Manzanares, Miguel A and Prater, Justin and Culp, David and Gold, Leslie I},
title = {Calreticulin accelerates corneal wound closure and mitigates fibrosis: Potential therapeutic applications},
journal = {Journal of Cellular and Molecular Medicine},
year = {2024},
doi = {10.1111/jcmm.18027}
}
EUVIMED